Top 200 Medicines Annual Report 2019: The king of medicines
Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.
Celltrion Shares Fall After FDA Issues Warning Letter
Shares of South Korea-based Celltrion were down more than 5 percent after the company announced it received a warning letter from the U.S. Food and Drug Administration after the regulatory agency inspected a company drug manufacturing facility.
Novartis Showcases 4 Potential Blockbusters in Its Late-Stage Pipeline
Swiss-based Novartis is showcasing four key drugs from the company’s late stage pipeline at an R&D and investor event in England.
FDA approves Cyltezo, a biosimilar to Humira
The FDA approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo, a biosimilar to Humira, in a pre-filled syringe for treating chronic inflammatory diseases.
Special Feature – First Year After Launch: The specialties win again
Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.
Novartis Enbrel copy delayed until at least 2018
The Novartis copy of Amgen’s blockbuster drug Enbrel will not go on sale until at least 2018 because of the U.S. company’s patent protection challenge.
Pfizer to ship Remicade biosimilar in November
Pfizer will begin shipping its biosimilar version of J&J’s rheumatoid arthritis drug Remicade in late November 2016 at a 15% discount to current wholesale prices.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!